食管鳞癌组织ERCC1及SLC7A11的表达水平对新辅助化疗疗效的影响

doi:10.3969/j.issn.1006-6233.2021.06.018

摘要
图/表
参考文献
相关文章 (8)

全文: PDF (1519 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要 目的: 观察ERCC1、SLC7A11在食管鳞癌组织中的表达水平,探讨其与食管鳞癌患者新辅助化疗疗效的相关性。方法: 采用免疫组化(SP)法检测92例食管鳞癌组织(实验组)和36例食管正常黏膜组织(对照组)中ERCC1和SLC7A11的表达量,并分析其与食管鳞癌患者临床病理特征的关系。结果: 食管鳞癌组ERCC1、SLC7A11表达阳性率高于对照组,有统计学差异(P<0.01)。ERCC1高表达与食管鳞癌的临床分期、分化程度及有无淋巴结转移有关(P<0.05),与性别、年龄无关(P>0.05)。SLC7A11高表达与食管鳞癌的临床分期、有无淋巴结转移、及分化程度有关(P<0.05),与性别、年龄无关(P>0.05)。Pearson相关分析显示,ERCC1表达水平与SLC7A11表达水平呈正相关。Kaplan-Meier分析显示ERCC1(+)/ SLC7A11(+)高表达的食管鳞癌患者治疗后3年复发率高于阴性表达患者,差异有统计学意义(P<0.05),3年总生存率均低于阴性表达患者(P<0.05)。81例接受新辅助化疗患者中,敏感组59例,耐药组22例,ERCC1在敏感组高表达,与对照组比较差异有显著性(P<0.01);SLC7A11在敏感组高表达,两组中表达差异显著(P<0.05)。结论: ERCC1(+)/ SLC7A11(+)高表达的食管鳞癌患者预后较差。因此,ERCC1、SLC7A11有可能作为食管鳞癌患者术前新辅助化疗的预后评估指标。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章

关键词 ：食管鳞癌, ERCC1, SLC7A11, 新辅助化疗

Abstract：Objective: To Observe the changes of ERCC1 and SLC7A11 expression in esophageal cancer tissue, and to explore the role of ERCC1 and SLC7A11 in esophageal cancer chemotherapy. Methods: The expression levels of ERCC1 and SLC7A11 in 92 cases of esophageal cancer tissue (experimental group) and 36 cases of normal esophageal mucosa tissue (control group) were detected by SP immunohistochemical method, and the relationship between the relative transcript levels and clinicopathological characteristics of patients with esophageal cancer was analyzed. Results: The positive rates of ERCC1 and SLC7A11 expression in esophageal cancer group were higher than those in control group (P<0.01). The high expression of ERCC1 was correlated with the clinical stages, differentiation degrees and lymph node metastasis of esophageal cancer (P<0.05), but not with gender and age (P>0.05).The high expression of SLC7A11 was correlated with the clinical stages, lymph node metastasis, and differentiation degrees of esophageal cancer (P<0.05), but not with gender and age (P>0.05).Pearson correlation analysis showed that ERCC1 expression level was positively correlated with SLC7A11 expression level.Kaplan-Meier analysis showed that the recurrence rate of esophageal cancer patients with ERCC1 (+)/SLC7A11 (+) high expression was also higher than that of patients with negative ERCC1/ SLC7A11 expression at 3 years after treatment. The difference was statistically significant (P<0.05). The overall survival rate at 3 years was lower than that of patients with negative expression (P < 0.05).Among 81 patients receiving neoadjuvant chemotherapy, there were 59 patients in the sensitive group and 22 patients in the drug resistant group. The positive expression rate of ERCC1 was significantly different between the two groups (P<0.01). The positive expression rate of SLC7A11 was significantly different between the two groups (P<0.05). Conclusion: The expression levels of ERCC1 and SLC7A1,to some extent, are of a certain guiding effect on preoperative neoadjuvant chemotherapy in patients with esophageal cancer, and the efficacy of neoadjuvant chemotherapy in patients with ERCC1 (+)/SLC7A11 (+) high expression is poor.

Key words： Esophageal cancer ERCC1 SLC7A11 Neoadjuvant chemotherapy

引用本文:

刘建伟, 徐世宗, 李立, 李建辉, 裴存文, 陈宝刚, 李建华. 食管鳞癌组织ERCC1及SLC7A11的表达水平对新辅助化疗疗效的影响[J]. 河北医学, 2021, 27(6): 963-967.
LUI Jianwei, XU Shizong, Li Li, et al. The Expression of ERCC1 and SLC7A11 in Esophageal Squamous Cell Carcinoma and its Relationship with the Efficacy of Neoadjuvant Chemotherapy. HeBei Med, 2021, 27(6): 963-967.

链接本文:

http://www.hbyxzzs.cn/CN/10.3969/j.issn.1006-6233.2021.06.018 或 http://www.hbyxzzs.cn/CN/Y2021/V27/I6/963

[1] Watanabe M, Otake R, Kozuki R, et al. Recent progress in multidisciplinary treatment for patients with esophageal cancer[J].Surg Today,2020,50(1):12~20.
[2] Fang W. Interpretation of 2017 national comprehensive cancer network (NCCN) guidelines for the diagnosis and treatment of esophageal squamous cell carcinoma through the new TNM staging of esophageal carcinoma (eighth edition) by the Union for international cancer control (UICC) and the American Cancer Commission (AJCC)[J].Zhonghua Wei Chang Wai Ke Za Zhi,2017,20(10):1122~1126.
[3] 朱厚鑫.术前新辅助化疗对局部进展期胃癌近期与远期预后的影响[D].青岛大学,2019.
[4] Duan M, Ulibarri J, Liu KJ, et al. Role of nucleotide excision repair in cisplatin resistance[J].Int Mol Sci,2020, 21(23):9248~9361.
[5] Lin W, Wang C, Liu G, et al.SLC7A11/xCT in cancer: biological functions and therapeutic implications[J].Am Cancer Res,2020,10(10):3106~312.
[6] Ando N, Kato H, Igaki H, et al. A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5- fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907)[J].Ann Surg Oncol,2012,19(1):68~74.
[7] 胡倩倩,王振辉,牛超,等.铂类抗肿瘤药物耐药机制研究进展[J].药学进展,2017,41(10):769~774.
[8] 黄玉亮,朱波.切除修复交叉互补基因1与肿瘤的关系研究进展[J].癌症进展,2019,17(4):376~379.
[9] Ozcan MF, Dizdar O, Dincer N, et al. Low ERCC1 expression is associated with prolonged survival in patients with bladder cancer receiving platinum-based neoadjuvant chemotherapy[J].Urol Oncol,2013, 31(8):1709.
[10] 潘婷婷,赵达,唐君霞,戴滋赢,周永宁,陈永林,关泉林.Ki-67、ERCC1的表达对胃癌新辅助化疗病理学缓解的预测价值[J].中国肿瘤,2019,28(7):543~548.
[11] Yin F, Yi S, Wei L, et al. Microarray-based identification of genes associated with prognosis and drug resistance in ovarian cancer[J].Cell Biochem,2019, 120(4):6057~6070.
[12] Horibe S, Kawauchi S, Tanahashi T, et al. CD44v-dependent upregulation of xCT is involved in the acquisition of cisplatin-resistance in human lung cancer A549 cells[J].BiochemBiophys Res Commun,2018, 507(1):426~432.